Merck's most recent trend suggests a bullish bias. One trading opportunity on Merck is a Bull Put Spread using a strike $60.50 short put and a strike $55.50 long put offers a potential 10.13% return on risk over the next 12 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $60.50 by expiration. The full premium credit of $0.46 would be kept by the premium seller. The risk of $4.54 would be incurred if the stock dropped below the $55.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Merck is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Merck is bullish.
The RSI indicator is at 71.38 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Merck
Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent
Mon, 08 Sep 2014 22:24:40 GMT
The Wall Street Journal – Bristol-Myers and Ono sued Merck, alleging that its new cancer drug, Keytruda, violates their patent on harnessing the body's immune system to fight cancer.
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Mon, 08 Sep 2014 21:00:00 GMT
Business Wire – Merck , known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda
Mon, 08 Sep 2014 19:30:12 GMT
Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug
Mon, 08 Sep 2014 14:18:39 GMT
Bristol-Myers sues Merck over U.S. immunotherapy patent
Sat, 06 Sep 2014 01:25:07 GMT
Reuters – Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. Immunotherapy is a mechanism that uses the body's own immune system to eliminate cancer cells. District Court of Delaware, Bristol-Myers said Merck was planning to exploit its invention with a later-developed treatment, pembrolizumab, violating the company's May 20 patent. Bristol-Myers is using its patented technology to develop its own drug, nivolumab, which is being tested in different areas of cancer including melanoma.
Related Posts
Also on Market Tamer…
Follow Us on Facebook